Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

32.27 -0.16 (-0.48%)
Streaming Delayed Price Updated: 1:34 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 86,069
Open 32.46
Bid (Size) 32.24 (2)
Ask (Size) 32.28 (4)
Prev. Close 32.42
Today's Range 32.15 - 32.46
52wk Range 25.53 - 40.28
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.
The company is working on a non-stimulant approach to treating ADHD. 
Via Investor's Business Daily

Performance

YTD
-11.4%
-11.4%
1 Month
-1.7%
-1.7%
3 Month
-11.1%
-11.1%
6 Month
+4.9%
+4.9%
1 Year
-4.4%
-4.4%

More News

Read More
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Earnings Scheduled For February 25, 2025
Via Benzinga
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
3 Small-Cap Stocks Skating on Thin Ice
Via StockStory
Supernus to Participate in Two Upcoming Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow
Via StockStory
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
Via StockStory
Viatris Earnings: What To Look For From VTRS
Via StockStory
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
Via StockStory
Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
Via StockStory
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
Via StockStory
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Via Benzinga
Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
Via Chartmill
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 32.27
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 03/28/25 01:34 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 1.71B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.